RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Celyad Oncology Stock

Celyad Oncology Net Income 2024

Celyad Oncology Net Income

20.21 M EUR

Ticker

CYAD.BR

ISIN

BE0974260896

WKN

A1W7Q9

In 2024, Celyad Oncology's profit amounted to 20.21 M EUR, a -339.26% increase from the -8.45 M EUR profit recorded in the previous year.

The Celyad Oncology Net Income history

YEARNET INCOME (undefined EUR)
2025e15.41
2024e20.21
2023-8.45
2022-40.94
2021-26.51
2020-17.2
2019-28.63
2018-37.43
2017-56.4
2016-23.61
2015-29.11
2014-16.45
2013-14.49
2012-13.52
2011-9.35
2010-6.71

Celyad Oncology Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Celyad Oncology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Celyad Oncology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Celyad Oncology’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Celyad Oncology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Celyad Oncology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Celyad Oncology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Celyad Oncology’s growth potential.

Celyad Oncology Revenue, EBIT and net profit per share

DateCelyad Oncology RevenueCelyad Oncology EBITCelyad Oncology Net Income
2025e156.25 M undefined-13.81 M undefined15.41 M undefined
2024e62.5 M undefined-10.67 M undefined20.21 M undefined
2023102,000 undefined-9.54 M undefined-8.45 M undefined
20220 undefined-5.77 M undefined-40.94 M undefined
20210 undefined-26.39 M undefined-26.51 M undefined
20205,000 undefined-16.98 M undefined-17.2 M undefined
20196,000 undefined-28.88 M undefined-28.63 M undefined
20183.12 M undefined-37.99 M undefined-37.43 M undefined
20173.54 M undefined-26.6 M undefined-56.4 M undefined
20168.52 M undefined-25.61 M undefined-23.61 M undefined
20153,000 undefined-29.67 M undefined-29.11 M undefined
2014146,000 undefined-16.44 M undefined-16.45 M undefined
20130 undefined-12.95 M undefined-14.49 M undefined
201250,000 undefined-12.9 M undefined-13.52 M undefined
20110 undefined-9.3 M undefined-9.35 M undefined
20101.52 M undefined-6.42 M undefined-6.71 M undefined

Celyad Oncology stock margins

The Celyad Oncology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Celyad Oncology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Celyad Oncology.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Celyad Oncology's sales revenue. A higher gross margin percentage indicates that the Celyad Oncology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Celyad Oncology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Celyad Oncology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Celyad Oncology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Celyad Oncology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Celyad Oncology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Celyad Oncology Margin History

Celyad Oncology Gross marginCelyad Oncology Profit marginCelyad Oncology EBIT marginCelyad Oncology Profit margin
2025e32.35 %-8.84 %9.86 %
2024e32.35 %-17.08 %32.34 %
202332.35 %-9,356.86 %-8,282.35 %
202232.35 %0 %0 %
202132.35 %0 %0 %
2020100 %-339,540 %-344,080.03 %
2019100 %-481,316.65 %-477,200 %
2018100 %-1,219.52 %-1,201.51 %
201785.45 %-751.5 %-1,593.08 %
201699.38 %-300.47 %-276.97 %
201566.67 %-989,066.7 %-970,466.7 %
2014-8,407.53 %-11,258.22 %-11,269.18 %
201332.35 %0 %0 %
2012-11,320 %-25,800 %-27,040 %
201132.35 %0 %0 %
2010-109.87 %-422.37 %-441.45 %

Celyad Oncology Aktienanalyse

What does Celyad Oncology do?

Celyad Oncology is a biotech company specializing in the discovery and development of new cancer immunotherapies. The company, headquartered in Mont-Saint-Guibert, Belgium, was founded in 2007 and has been listed on the NASDAQ and Euronext stock exchanges since September 2015. The history of Celyad Oncology began with the discovery of CAR-T therapy, which is based on the tumor cell recognition by T cells of the body's immune system. In 2001, researchers at the University of Leuven (Belgium) introduced a new method for culturing T cells, which was a major step in the development of CAR-T therapy. In 2004, the researchers founded Celyad with the aim of developing clinically effective CAR-T therapies. In 2015, the company was renamed Celyad Oncology to emphasize its strategic focus on oncology products. Celyad Oncology has developed a unique business model that focuses on the clinical development of CAR-T cell therapies. The company uses innovative technologies such as allogeneic CAR-T cells, which come from donor tissue from persons other than the patient. These cells have the advantage of being able to be produced in unlimited quantities, enabling the rapid and cost-effective manufacturing of CAR-T cells. In addition, the company has developed a platform technology called "shRNA" that regulates gene expression in T cells, thereby improving the safety and efficacy of CAR-T therapies. The company is divided into various divisions, from preclinical research to the clinical development and commercialization of CAR-T therapies. Celyad Oncology has several product candidates in various stages of development, focusing on indications such as multiple myeloma, acute myeloid leukemia (AML), and solid tumors. One of Celyad Oncology's most promising product candidates is CYAD-01, a CAR-T cell product targeting the CD19 protein. It is currently in a Phase I/IIa clinical trial evaluating the safety and efficacy of CYAD-01 in patients with refractory or relapsed CD19+ B-cell lymphoma. In October 2020, the product candidate achieved a complete response in a patient with a different indication, acute myeloid leukemia (AML). Another product candidate is CYAD-101, an allogeneic CAR-T cell product targeting the NKG2D protein. This protein is overexpressed on many cancer cells but not on healthy cells. CYAD-101 is currently in a Phase I/II clinical trial for the treatment of various tumor types, including lung cancer and pancreatic cancer. Celyad Oncology also collaborates with other companies to further develop its technologies and product candidates. In 2018, the company entered into a partnership with Novartis to utilize Celyad Oncology's CAR-T platform technology for the development of products for solid tumors. In 2019, Celyad Oncology announced a partnership with ONO Pharmaceutical to accelerate the development of CYAD-211, an allogeneic CAR-T cell product for the treatment of multiple myeloma. In summary, Celyad Oncology has not only a unique business model but also promising product candidates and technologies that have the potential to revolutionize the treatment of cancer. With a strong pipeline and targeted clinical development, Celyad Oncology is well positioned to continue its success in the future. Celyad Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Celyad Oncology's Profit Margins

The profit margins of Celyad Oncology represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Celyad Oncology's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Celyad Oncology's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Celyad Oncology's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Celyad Oncology’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Celyad Oncology stock

How much profit has Celyad Oncology made this year?

Celyad Oncology has made 20.21 M EUR this year.

How has the profit developed compared to last year?

The profit has increased by -339.26% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Celyad Oncology publish its earnings?

Celyad Oncology publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Celyad Oncology?

The profits of Celyad Oncology are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Celyad Oncology?

You can learn more about the earnings of Celyad Oncology by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Celyad Oncology pay?

Over the past 12 months, Celyad Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Celyad Oncology is expected to pay a dividend of 0 EUR.

What is the dividend yield of Celyad Oncology?

The current dividend yield of Celyad Oncology is .

When does Celyad Oncology pay dividends?

Celyad Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Celyad Oncology?

Celyad Oncology paid dividends every year for the past 0 years.

What is the dividend of Celyad Oncology?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Celyad Oncology located?

Celyad Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Celyad Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Celyad Oncology from 9/29/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Celyad Oncology pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Celyad Oncology in the year 2023?

In the year 2023, Celyad Oncology distributed 0 EUR as dividends.

In which currency does Celyad Oncology pay out the dividend?

The dividends of Celyad Oncology are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Celyad Oncology

Our stock analysis for Celyad Oncology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Celyad Oncology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.